Find in Library

<p>Background. Bleeding in acquired hemophilia A patients with FVIII autoantibodies is often severe. The authors describe a successfuly acquired hemophilia A treatment with Feiba, glucocorticoids and cyclophosphamide in three patients.</p><p>Results. In a 66-year patient with chest hematoma and m. iliopsoas hematoma, APTT 50.1 s, FVIII 0.05 IU/mL and inhibitors FVIII (anti-FVIII) 22 BU/ml were found. After treatment of hemorrhages with Feiba, dexamethasone and cyclophosphamide, FVIII increased to 0.54 IU/mL and no inhibitors were found on day seventeen. In a 46-year patient with advanced AIDS, multiple hematomas and liver cirrhosis after HCV infection, the platelet count was 92 × 109/L, APTT 48.2 s, FVIII 0.05 IU/mL and anti-FVIII 1.7 BU/mL. The hemorrhages were treated with FEIBA and methylprednisolone therapy was started after 14 months. After 42 days FVIII increased to 0.56 IU/mL and no inhibitors were found. In a 69-year patient suffering from thyroiditis and idiopathic thrombocytopenic purpura, extensive gluteal and chest hematomas were detected during the maintenance therapy with methylprednisolone 16 mg/day. The thrombocyte count was normal but APTT 48.8 s, FVIII 0.01 IU/mL and anti-FVIII 7.0 BU/mL was found. FVIII activity were 1.72 IU/mL and no inhibitors was noted after 330-days of treatment with cyclophosphamide.</p><p>Conclusions. The treatment with FEIBA was effective in stopping the hemorrhages. The glucocorticoids were efficient in prompt decreasing of the inhibitor titer whereas the effect of cyclophosphamide was retarded.<br /><br /></p>